<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01939418</url>
  </required_header>
  <id_info>
    <org_study_id>NCCCTS-13-670</org_study_id>
    <secondary_id>12491</secondary_id>
    <nct_id>NCT01939418</nct_id>
  </id_info>
  <brief_title>Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer</brief_title>
  <official_title>A Phase Ib Trial of Gemcitabine and Cisplatin With RAD001 in Patients With Metastatic Triple Negative Breast Cancer Proceeding to an Open Label Randomized Phase II Trial Comparing Gemcitabine/Cisplatin With or Without RAD001.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study consists of two parts. In a phase Ib part, investigators will explore the&#xD;
      recommended dose of gemcitabine, cisplatin, and RAD001 combination in patients with&#xD;
      metastatic TNBC. After completing the phase Ib part, investigators will review the data and&#xD;
      discuss with Novartis before the start of a phase II part. In the phase II part,&#xD;
      investigators will compare the efficacy of the gemcitabine and cisplatin with or without&#xD;
      RAD001 in patients with metastatic TNBC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PIK3CA active mutations are the most frequent genetic event in breast cancer, including in&#xD;
      TNBC which presents activated PI3K/AKT signaling due to PIK3CA mutation or PTEN deficiency.&#xD;
      TNBC cell lines having activated PI3K/AKT signaling showed a high sensitivity to PI3K/mTOR&#xD;
      inhibitors. RAD001 is a potent mTOR complex 1 inhibitor and showed to enhance cisplatin or&#xD;
      gemcitabine induced apoptosis by inhibiting p53 induced p21 expression.&#xD;
&#xD;
      This study consists of two parts. In a phase Ib part, investigators will explore the&#xD;
      recommended dose of gemcitabine, cisplatin, and RAD001 combination in patients with&#xD;
      metastatic TNBC. After completing the phase Ib part, investigators will review the data and&#xD;
      discuss with Novartis before the start of a phase II part. In the phase II part,&#xD;
      investigators will compare the efficacy of the gemcitabine and cisplatin with or without&#xD;
      RAD001 in patients with metastatic TNBC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">August 2013</start_date>
  <completion_date type="Actual">July 30, 2017</completion_date>
  <primary_completion_date type="Actual">July 30, 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The recommended dose of the combination of gemcitabine, cisplatin and RAD001 (everolimus) in patients with metastatic triple-negative breast cancer</measure>
    <time_frame>up to 1 year</time_frame>
    <description>phase IB part</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of gemcitabine and cisplatin with or without RAD001 in patients with metastatic triple-negative breast cancer by evaluating progression free survival (PFS)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>phase II part</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of gemcitabine/cisplatin/RAD001</measure>
    <time_frame>up to 1 year</time_frame>
    <description>phase Ib part</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with adverse events as a measure of safety and tolerability</measure>
    <time_frame>up to 5 years</time_frame>
    <description>phase Ib and phase II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>up to 1 year</time_frame>
    <description>phase Ib and phase II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>phase Ib and phase II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>check biomarkers associated with the response of RAD001: angiogenesis, metabolism, immune cells profiles</measure>
    <time_frame>up to 5 years</time_frame>
    <description>phaseIb and phaseII</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>RAD001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gemcitabine 800mg/m2, D1 and D8 iv. every 3 weeks. cisplatin 30mg/m2, D1 and D8 iv. every 3 weeks. RAD001 5mg QD. po.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAD001</intervention_name>
    <description>Afinitor 5mg qd. po.</description>
    <arm_group_label>RAD001</arm_group_label>
    <other_name>Afinitor</other_name>
    <other_name>everolimus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>gemcitabine 800mg/m2 iv. D1 and D8 every 3 weeks</description>
    <arm_group_label>RAD001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>cisplatin 30mg/m2 iv. D1 and D8 every 3 weeks</description>
    <arm_group_label>RAD001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females with histologically confirmed, metastatic or stage IV breast cancer&#xD;
&#xD;
          -  ER/PgR negative or poor (Allred score ≤ 3/8) and HER2 negative breast cancer&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Age ≥ 20 years&#xD;
&#xD;
          -  Previously treated by anthracycline and taxane in adjuvant/neoadjuvant or metastatic&#xD;
             setting&#xD;
&#xD;
          -  ≤ 2 chemotherapy regimens for metastatic disease&#xD;
&#xD;
          -  Radiological or objective evidence of recurrence or progression on or after the last&#xD;
             systemic therapy prior to enrolment.&#xD;
&#xD;
          -  CNS metastasis is permitted if asymptomatic and not requiring treatment with steroids&#xD;
             and is documented to be non-progressing at study entry&#xD;
&#xD;
          -  Presence of measurable or evaluable disease by RECIST 1.1 criteria&#xD;
&#xD;
          -  Adequate hematopoietic function: Absolute granulocyte count ≥1,500/mm3, platelet&#xD;
             ≥100,000/mm3, hemoglobin ≥ 10g/mm3&#xD;
&#xD;
          -  Adequate hepatic function: total bilirubin ≤ 1.5 x upper normal limit (UNL), AST/ALT&#xD;
             ≤2.5 x UNL or ≤5 x UNL if presented with hepatic metastasis&#xD;
&#xD;
          -  Fasting serum cholesterol ≤ 300mg/dl and fasting triglycerides ≤ 2.5 x UNL&#xD;
&#xD;
          -  Adequate renal function: Serum creatinine ≤1.5mg/dL&#xD;
&#xD;
          -  Patients should sign a written informed consent before study entry&#xD;
&#xD;
          -  Patients with positive HBV-DNA of HBsAg at screening must initiate prophylaxis with&#xD;
             appropriate antiviral medication at least one week prior to treatment start&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known active CNS metastasis&#xD;
&#xD;
          -  Patients who received prior therapy with gemcitabine&#xD;
&#xD;
          -  Patients with only non-measurable lesions other than bone metastasis (e.g. pleural&#xD;
             effusion, ascites).&#xD;
&#xD;
          -  Patients with more than 3 prior chemotherapy lines for treating metastatic breast&#xD;
             cancer.&#xD;
&#xD;
          -  Patients who received prior therapy with mTOR inhibitor or PI3K inhibitor&#xD;
&#xD;
          -  Known hypersensitivity to mTOR inhibitors, e.g. Sirolimus (rapamycin).&#xD;
&#xD;
          -  Radiotherapy within four weeks prior to enrolment, except radiotherapy to the bone for&#xD;
             analgesic purpose or for lytic lesions at risk of fracture. Patients must have&#xD;
             recovered from radiotherapy toxicities prior to enrolment.&#xD;
&#xD;
          -  Patients who have history of cancer other than in situ uterine cervix cancer or&#xD;
             nonmelanotic skin cancer&#xD;
&#xD;
          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly&#xD;
             alter the absorption of oral everolimus&#xD;
&#xD;
          -  Active ulceration of upper gastrointestinal tract&#xD;
&#xD;
          -  Other concurrent severe and/or uncontrolled conditions (e.g. uncontrolled diabetes&#xD;
             mellitus, active untreated or uncontrolled infection, chronic obstructive or chronic&#xD;
             restrictive pulmonary disease including dyspnea at rest from any cause) that could&#xD;
             cause unacceptable safety risks or compromise compliance with the protocol.&#xD;
&#xD;
          -  Patients with a known history of HIV seropositivity. Screening for HIV infection at&#xD;
             baseline is not required.&#xD;
&#xD;
          -  Significant symptomatic deterioration of lung function. If clinically indicated,&#xD;
             pulmonary function tests including measures of predicted lung volumes, DLco, O2&#xD;
             saturation at rest on room air should be considered to exclude restrictive pulmonary&#xD;
             disease, pneumonitis or pulmonary infiltrates.&#xD;
&#xD;
          -  Patients being treated with drugs recognized as being strong inhibitors or inducers of&#xD;
             the isoenzyme CYP3A at enrolment (rifabutin, rifampicin, clarithromycin, ketoconazole,&#xD;
             itraconazole, voriconazole, ritonavir, telithromycin) continuously for at least 7 days&#xD;
             during any time period in the last 2 weeks prior to enrolment&#xD;
&#xD;
          -  Known hypersensitivity to protocol treatment&#xD;
&#xD;
          -  Pregnant or breast feeding&#xD;
&#xD;
          -  Peripheral neuropathy ≥ grade 2 (NCI CTCAE version 4.0) at randomization&#xD;
&#xD;
          -  Patients unwilling to or unable to comply with the protocol&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In Hae Park, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center, Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National cancer center</name>
      <address>
        <city>Goyangsi</city>
        <state>Gyeonggido</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>August 28, 2013</study_first_submitted>
  <study_first_submitted_qc>September 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2013</study_first_posted>
  <last_update_submitted>October 1, 2017</last_update_submitted>
  <last_update_submitted_qc>October 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>In Hae Park</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>metastatic breast cancer</keyword>
  <keyword>triple negative breast cancer</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>RAD001</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

